Literature DB >> 24404368

Prevention of renal damage by treating hyperuricemia.

Azar Nickavar1.   

Abstract

Nephrolithiasis, obstructive renal failure, essential hypertension, and chronic tubulointerstitial nephritis have been considered as the renal complications of hyperuricemia. Massive proteinuria has been rarely reported as the primary manifestation of increased serum uric acid. This is the report of a child presented with proteinuira, hypertension, and glomerular scelrosis secondary to hypouricosuric hyperuricemia, who was treated by uric acid lowering management.

Entities:  

Keywords:  Glomerular sclerosis; hypertension; hyperuricemia; proteinuria

Year:  2013        PMID: 24404368      PMCID: PMC3883258     

Source DB:  PubMed          Journal:  Int J Prev Med        ISSN: 2008-7802


INTRODUCTION

Uric acid is the end product of human purine metabolism. Increased serum uric acid has been considered with different metabolic, cardiovascular, and renal disorders.[1] Glomerular, tubulointerstitial, and vascular involvement[2] with eventual chronic renal disease has been reported in hyperuricemia.[34] Recognition of the different manifestations and complications of hyperuricemia seems beneficial to prevent renal damage in the early phase.

CASE REPORT

A 2 year and 9 months girl was admitted for seizure, severe hypertension (200/110), and renal failure. She had a previous admission in another hospital for isolated proteinuria, with no clinical follow-up. Family history was negative for any previous renal disease. Laboratory exams [Table 1] revealed hyperuricemia (uric acid: 18 mg/dl), increased serum creatinine, microscopic hematuria, and nephrotic syndrome. Liver function tests, serum cathecolamines, LDH, vitamin B12, and complement level, were normal. ANA, anti-dsDNA, ANCA, anti-GBM, rubella, CMV and HCV antibody, BK virus, HBS ag, and urine MPS were all negative. Serum level of renin and aldestrone was elevated. Decreased urinary excretion with increased serum level of uric acid (hypouricosuric hyperuricemia) confirmed by excluding all other causes of hyperuricemia. Normal to mild renal enlargement with bilateral increased echogenicity and increased resistive index in favor of parenchymal renal disease with no renal stenosis detected in ultrasound exam. Voiding cystouretherography was normal. Severe diastolic dysfunction with concentric left ventricular hypertrophy and decreased ejection fraction in favor of chronic hypertension were documented in echocardiography.
Table 1

Laboratory variables at presentation and post treatment

Laboratory variables at presentation and post treatment Peritoneal dialysis was performed for acute renal failure in addition to antihypertensive treatment. Renal biopsy showed diffuse global sclerosis with glomerular hypertrophy, increased mesengial cellularity, segmental solidification, tubular atrophy, focal inflammation, and arterial narrowing with the impression of ESRD and end arteritis fibrosa, suggested the possible changes of chronic malignant hypertension superimposed on focal segmental glomerulosclerosis [Figure 1]. Immunoflourescence study was negative.
Figure 1

Diffuse global glomeruli sclerosis (×400, PAS stain)

Diffuse global glomeruli sclerosis (×400, PAS stain) Despite of improved renal function (serum creatinine: 0.8 mg/dl), serum uric acid was persistently elevated in repeated samples with low urine uric acid. A second renal biopsy performed for disproportional improved renal function compared to distorted renal biopsy revealed segmental and global glomerular sclerosis, mild to moderate hyperplasia in small arterioles and chronic inflammation with interstitial fibrosis [Figure 2]. Therefore, the first renal biopsy assumed to be taken from a nidus of glomerular sclerosis. As a primary focal segmental glomerular sclerosis, she was treated with corticosteroids followed by conventional immunosuppressive treatments (cyclosporine, mycophenolate mofetile), with no clinical response. But, proteinuria decreased significantly by uric acid lowering agents. Genetic analysis revealed no documented mutation for common NPHS2 gene mutation. During the follow-up period on allopurinole and anti-proteinuirc treatment, the patient had normal renal function with mild to moderate proteinuria and no recurrence of nephrotic syndrome.
Figure 2

Segmental sclerosis in one glomerule (×400, PAS stain)

Segmental sclerosis in one glomerule (×400, PAS stain)

DISCUSSION

Hyperuricemia occurs in conditions with uric acid over production such as ketogenic diet, increased intake of purine rich diets, HPRT or ARPT deficiency, or PRPP overactivity, cellular proliferation, malignancies, and rhabdomyolysis, or decreased uric acid excretion in chronic kidney disease, diabetic ketoacidosis, starvation, and volume contraction. Miscellaneous causes of hyperuricemia include metabolic syndrome, hypothyroidism, hyperparathyroidism, SIADH syndrome, GSD type 1, sarcoidosis, and drug administration.[56] Familial juvenile hyperuricemic nephropathy is an inherited disorder characterized by hypouricosuric hyperuricemia, progressive tubulointerstitial nephritis, and chronic renal failure and is considered as the possible underlying disease in this patient.[7] Nephrolithiasis is the most common renal involvement in hyperuricemia, complicated by acute obstructive renal failure.[3] A pathogenic link has been reported between hyperuricemia and essential hypertension through activation of renin–angiotensin system, downregulation of nitric oxide, vascular muscle proliferation, afferent arteriolosclerosis, altered pressure natriuresis, endothelial dysfunction, and abnormal cellular sodium transport.[8910] Lowering uric acid level controls hypertension in some patients initially,[9] becomes irreversible, salt sensitive, and resistant to uric acid lowering treatment later.[11] In addition, moderate degrees of asymptomatic hyperuricemia are not injurious to the kidney.[6] But, interstitial damage occurs more commonly in hyperuricemic gout.[12] Glomerular hypertrophy/hypertension, afferent arteriolar sclerosis, and macrophage infiltration,[4] vasoconstriction, chronic ischemia, morphologic changes similar to focal mesangio-capillary or mesangial proliferative glomerulonephritis with increased mesangial cells and matrix, focal segmental glomerular sclerosis, capillary basement membrane thickening, and chronic tubulointerstitial damage progressive to end-stage kidney disease have been reported in chronic hyperuricemia.[131415] This patient had persistent proteinuira originated from glomerular sclerotic lesions secondary to chronic hypouricosuric hyperuricemia. Proteinuria decreased significantly by uric acid lowering agents and antiproteinuirc treatment. Therefore, measurement of serum uric acid and early treatment of hyperuricemia are recommended in patients with idiopathic proteinuria to prevent further renal damage.
  13 in total

Review 1.  Serum uric acid: a risk factor and a target for treatment?

Authors:  Daniel I Feig; Marilda Mazzali; Duk-Hee Kang; Takahiko Nakagawa; Karen Price; John Kannelis; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2006-04       Impact factor: 10.121

Review 2.  Uric acid--a uremic toxin?

Authors:  Takahiko Nakagawa; Marilda Mazzali; Duk-Hee Kang; L Gabriela Sánchez-Lozada; Jaime Herrera-Acosta; Richard J Johnson
Journal:  Blood Purif       Date:  2006       Impact factor: 2.614

3.  The role of uric acid in pediatric hypertension.

Authors:  Daniel I Feig; Richard J Johnson
Journal:  J Ren Nutr       Date:  2007-01       Impact factor: 3.655

4.  Hyperuricemia.

Authors:  A I Rae
Journal:  Can Fam Physician       Date:  1981-02       Impact factor: 3.275

Review 5.  Pharmacological treatment of acute and chronic hyperuricemia in kidney diseased patients.

Authors:  Guido Bellinghieri; Domenico Santoro; DVincenzo Savica
Journal:  Contrib Nephrol       Date:  2005       Impact factor: 1.580

Review 6.  Uric acid and hypertension.

Authors:  Daniel I Feig; Duk-Hee Kang; Takahiko Nakagawa; Marilda Mazzali; Richard J Johnson
Journal:  Curr Hypertens Rep       Date:  2006-05       Impact factor: 5.369

Review 7.  [Hypertension and hyperuricemia].

Authors:  A Hirai; Y Saitoh
Journal:  Nihon Rinsho       Date:  1996-12

8.  Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy.

Authors:  Frédéric Preitner; Olivier Bonny; Alexandra Laverrière; Samuel Rotman; Dmitri Firsov; Anabela Da Costa; Salima Metref; Bernard Thorens
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-21       Impact factor: 11.205

Review 9.  Tubulointerstitial disease: role of ischemia and microvascular disease.

Authors:  Takahiko Nakagawa; Duk-Hee Kang; Ryuji Ohashi; Shin-ichi Suga; Jaime Herrera-Acosta; Bernardo Rodriguez-Iturbe; Richard J Johnson
Journal:  Curr Opin Nephrol Hypertens       Date:  2003-05       Impact factor: 2.894

10.  Familial hyperuricemia and renal disease.

Authors:  P U Massari; C H Hsu; R V Barnes; I H Fox; P W Gikas; J M Weller
Journal:  Arch Intern Med       Date:  1980-05
View more
  1 in total

1.  Comment on: Prevention of Renal Damage by Treating Hyperuricemia.

Authors:  Hamid Nasri; Mohammad-Reza Ardalan; Mahmoud Rafieian-Kopaei
Journal:  Int J Prev Med       Date:  2015-02-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.